Core Viewpoint - A class action securities lawsuit has been filed against Telix Pharmaceuticals Ltd. alleging securities fraud that affected investors between February 21, 2025, and August 28, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [2]. - It is alleged that the quality of Telix's supply chain and partners was also materially overstated [2]. - As a result, statements made by defendants regarding Telix's business, operations, and prospects were materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until January 9, 2026, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the United States [4].
TLX LAWSUIT ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline